Next generation immune cell engagers

Our multispecific antibodies are designed to enhance and direct the power of key effector cells of the innate and adaptive immune system, providing a safer, more tailored alternative to CD3 based engagers.

Cytospire’s Purpose and Mission

Purpose

To improve patients’ lives by channelling our passion, science and curiosity into medicines that matter.

Our Approach

Mission

To develop next generation γδ T cell engagers into impactful cancer therapies, enabled by our unique expertise and talented team.

Mission

To develop next generation γδ T cell engagers into impactful cancer therapies, enabled by our unique expertise and talented team.

Learn about our team

View open positions

Led by a world class management team

With a successful entrepreneurial track record and supported by a syndicate of top investors, Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers.

Led by a world class management team

With a successful entrepreneurial track record and supported by a syndicate of top investors, Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers.

Latest News

Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer

Cytospire Therapeutics CEO, Natalie Mount, recognised as Woman Entrepreneur of the Year at 2025 Cancer Research Horizons Innovation and Entrepreneurship Awards